![]() | |
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C14H9ClN2O3S |
Molar mass | 320.75 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Tenidap was a COX/5-LOX inhibitor and cytokine-modulating anti-inflammatory drug candidate[1] that was under development by Pfizer as a promising potential treatment for rheumatoid arthritis,[2] but Pfizer halted development after marketing approval was rejected by the FDA in 1996[3] due to liver and kidney toxicity, which was attributed to metabolites of the drug with a thiophene moiety that caused oxidative damage.[4]
| |
---|---|
pyrazolones / pyrazolidines |
|
salicylates |
|
acetic acid derivatives and related substances |
|
oxicams |
|
propionic acid derivatives (profens) |
|
n-arylanthranilic acids (fenamates) |
|
COX-2 inhibitors (coxibs) |
|
other |
|
NSAID combinations |
|
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
|
![]() | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |